Sage Journals: Discover world-class research

Abstract

Keywords

ligelizumab chronic spontaneous urticaria omalizumab chronic urticaria

Get full access to this article

View all access options for this article.

References

Netchiporouk

Sasseville

Moreau

Habel

Rahme

Ben-Shoshan

. Evaluating comorbidities, natural history, and predictors of early resolution in a cohort of children with chronic urticaria. JAMA Dermatol. 2017;153(12):1236-1242.doi:10.1001/jamadermatol.2017.3182

Zuberbier

Aberer

Asero

et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414.doi:10.1111/all.13397

Maurer

Rosén

Hsieh

H-J

et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-935.doi:10.1056/NEJMoa1215372

Arm

JP.

Bottoli

Skerjanec

et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44(11):1371-1385.doi:10.1111/cea.12400

Maurer

Giménez-Arnau

AM.

Sussman

et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381(14):1321-1332.doi:10.1056/NEJMoa1900408

Gauvreau

GM.

Arm

JP.

Boulet

L-P

et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J Allergy Clin Immunol. 2016;138(4):1051-1059.doi:10.1016/j.jaci.2016.02.027

Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria

Abstract

Keywords

Get full access to this article

References